Myogen (MYOG) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myogen (MYOG)

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: michael_f_murphy who started this subject	11/17/2003 2:40:56 PM
From: tuck	Read Replies (1) of 50

Trying to see what MYOG has that others don't . . . A snip from the S-1: >>The most significant therapeutic advance for patients with moderate to severe pulmonary arterial hypertension took place in December 2001 with the approval of Tracleer, a twice-a-day oral formulation of bosentan, a non-selective ETRA. Tracleer was demonstrated in clinical trials to improve exercise capacity and quality of life. We believe that ambrisentan could have several additional clinical benefits over existing therapies, including: • lower incidence of liver toxicity; • once daily dosing based on its half-life; and • lower incidence of adverse interactions with other drugs, including anticoagulants.<< A snip from a recent (10/28) Dow Jones article: >>Analysts say Tracleer could have sales of at least $500 million a year, and perhaps as much as $1 billion if Actelion can win approval in other applications such as pulmonary fibrosis.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext